Skip to main content

This job has expired

You will need to login before you can apply for a job.

General Ledger / Senior Accountant

Employer
Scilex Holding Company
Location
Palo Alto, CA
Start date
Jun 7, 2024

View more

Discipline
Administration, Accounting
Required Education
Bachelors Degree
Position Type
Full time
Hotbed
Biotech Bay

Job Details

Salary Range: $100,000 - $125,000 

The pay range for this position is expected to be between $100,000 - $125,000/annually; however, the base pay offered may vary depending on multiple individualized factors, including market location, job-related knowledge, skills and experience.  The total compensation package for this position also includes medical benefits, 401(k) eligibility, vacation, sick time, and parental leave.  Additional details of participation in these benefit plans will be provided if an employee receives an offer of employment.    

If hired, employee will be in an “at-will position” and the Company reserves the right to modify base salary (as well as any other payment or compensation program) at any time, including reasons related to individual performance, Company or individual department/team performance, and market factors.   

Scilex Holding Company’s pay range data is provided in accordance with local state pay transparency regulations.  Scilex Holding Company may post different minimum wage ranges for permanent residency petitions pursuant to US Department of Labor requirements.     

Scilex Holding Company is committed to equal employment opportunities, and a workplace that embraces diversity and inclusion for qualified individuals of all backgrounds.   

About Scilex 

SCILEX HOLDING COMPANY (Nasdaq: SCLX, “Scilex”), is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain.  We are uncompromising in our focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life.

The company’s lead product ZTlido® (lidocaine topical system) 1.8%, is a marketed prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with Post-Herpetic Neuralgia (PHN), which is a form of post-shingles nerve pain. ZTlido® possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period.  Click here for ZTLido’s Important Safety Information and US Prescribing Information

We have acquired two FDA approved non-opioid pain products, GLOPERBA and ELYXYBTM, for the treatment of gout in adults and oral solution for the acute treatment of migraine, with or without aura, in adults. We launched ELYXYBTM in the U.S. in April 2023 and are planning to commercialize GLOPERBA in 2024.

Our three product candidates are (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXATM”), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica and has received Fast Track Status from the FDA. Currently there is no FDA approved non-opioid epidural injection to treat lumbosacral radicular pain, or sciatica; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a Phase 2, next-generation, triple-strength formulation of ZTlido, for the treatment of low back pain (“LBP”) and has received Fast Track Status from the FDA; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.  If these product candidates are approved by the FDA, we believe each of them could become the treatment option for their respective indications in the United States. 

SCILEX is committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to those who need them the most. Scilex Pharmaceuticals and Semnur Pharmaceuticals are wholly-owned subsidiaries of Scilex Holding Company.

Role and Responsibilities

  • Collaborating with internal departments to gather, analyze, and interpret relevant financial information.
  • Performing audits on financial data to assure its accuracy and truthfulness.
  • Ensuring that financial information complies with professional and regulatory standards.
  • Entering financial data such as accruals, deferrals, reclassifications, and interdepartmental entries into the ledger on a monthly basis, as well as preparing reports.
  • Performing account analysis to ensure that journal entries and balances are correct.
  • Reconciling accounts with the general ledger.
  • Gathering supporting documentation and performing recordkeeping.
  • Reconcile intercompany account and support financial statement consolidations;
  • Manage fixed assets schedule.
  • Prepare lease schedule and JEs.
  • Rollforward intangibles and other assets.
  • Assists Management with various special projects and ad hoc reporting.
  • Working on multiple projects simultaneously in a fast pace, dynamic environment

Qualifications and education requirements  

  • BA Accounting, Finance or Economics,
  • Minimum 7 years of progressive experience in General Accounting, AP/AR roles.
  • Knowledge of Generally Accepted Accounting Principles (GAAP).
  • Strong analytical and accounting skills and good understanding of U.S Generally accepted accounting principles (GAAP) and Sarbanes-Oxley (SOX)
  • Proficient in Microsoft Outlook, Word and Excel, Bill.com, Concur, preferred NetSuite or other ERP system.
  • Preferred experience in a mid/large-sized publicly traded corporation
  • Highly Organized with a strong attention to detail, clarity, accuracy, and conciseness

Company

SCILEX HOLDING COMPANY (Nasdaq: SCLX, “Scilex”), majority-owned by Sorrento, is dedicated to the development and commercialization of non-opioid pain management products. We are uncompromising in our focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life.

The company’s lead product ZTlido® (lidocaine topical system) 1.8%, is a branded prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with Post-Herpetic Neuralgia (PHN), which is a form of post-shingles nerve pain.

Scilex’s SP-102 (10 mg dexamethasone sodium phosphate viscous gel injection), or SEMDEXA™, for the treatment of Lumbar Radicular Pain has completed enrollment in a Phase III clinical trial and has received Fast Track Status from the FDA. If approved by the FDA, the company expects SP-102 to be the first FDA-approved non-opioid epidural injection to treat lumbosacral radicular pain, or sciatica, with the potential to replace 10 to 11 million off-label epidural steroid injections administered each year in the US.

SCILEX is committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to those who need them the most.

Scilex Pharmaceuticals and Semnur Pharmaceuticals are wholly-owned subsidiaries of Scilex Holding Company.

Company info
Website
Phone
(650) 516-4310
Location
960 San Antonio Road
Palo Alto
California
94303
US

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert